SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Immunomedics (IMMU) - moderated
An SI Board Since September 2006
Posts SubjectMarks Bans Symbol
63392 357 15 IMMU
Emcee:  idahoranch1 Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
61032Same sense about the SAVA data as jargonweary. The data was good, though perhaallatwwk18/3/2022
61031I feel pretty good about the data released by SAVA this morning. I am far from ajargonweary-8/3/2022
61030I apologize for calling Dr. Bordey a hack. She is not.ghettogoulash-8/3/2022
61029Clearly someone pointed out the $18k error. It is a non-issue and SAVA refiled Davidoff-8/3/2022
61028Gilead Notes from this quarter results: Turning to Oncology, and beginning withsummer_sky98/3/2022
61027I've been wondering why we would lend our drug out to someone else in the fighettogoulash-8/3/2022
61026Correction: Yale has renamed PTI-125 (Simufilam) as NT-125 in their pursuit of Ighettogoulash-8/3/2022
61025This is probably the final determination by the SEC of Cassava Sciences-- an $18ghettogoulash-8/3/2022
61024In a nutshell, "Amyloid drugs" remove already formed plaques with dubighettogoulash-8/3/2022
61023The issue of Aduhelm is that the FDA decided to approve the drug based on it fitallatwwk28/3/2022
61022That's great news! Congrats to you as well.ghettogoulash-8/3/2022
61021This article has nothing to do with Cassava Sciences, only that this "sleutghettogoulash18/3/2022
61020Simufilam history: From research funded by Cassava Sciences (then Pain Therapeutscorman118/2/2022
61019Yes, I agree that it would be very difficult for someone in the FDA to just killOlecranon-8/1/2022
61018Urslor: re SAVA: I think Jargonweary's post # 61024 answers the question weerickerickson28/1/2022
61017I very strongly suspect that the FDA has two equally strong yet competing desirejargonweary38/1/2022
61016allatwwk, I agree your analysis makes great sense. My concern is this: The FDA Olecranon-8/1/2022
61015"Agree article is essentially not as damning to SAVA as it is to the whole Stanley Lake 92-8/1/2022
61014Agree article is essentially not as damning to SAVA as it is to the whole concepurslor-8/1/2022
61013CBAY completes enrollment for RESPONSE PIII trial CymaBay Completes Enrollment erickerickson68/1/2022
61012There's some discussion of this article starting at message # 60977. My oveerickerickson-8/1/2022
61011Fascinating article and really harsh, though less so on SAVA. What is missing, allatwwk18/1/2022
61010SAVA...long article just showed up in my neurology news [Doximity] from science urslor17/31/2022
61009Did you inquire of your patient if s/he had been an IMMU shareholder? If so, thaFitzhughlaw67/30/2022
61008OT-Just a little shout out to board member Tinfoil Hat. I was prompted to thinkstockdoc7747/30/2022
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News